Scholar Rock's Study Reveals SRK-439's Potential Influence on Muscle Mass and Metabolic Health in Weight Loss Efforts.

Naltrexone, an opioid antagonist, has been utilized for treating addiction to both drugs and alcohol.

Orchard Therapeutics Reveals Enrollment of Initial Participant in Key Study of OTL-203 Targeting Hurler's Syndrome in MPS-I.

The phase II trial of mFOLFIRINOX, followed by hepatic infusion of floxuridine & dexamethasone with mFOLFIRI as first-line treatment in intrahepatic cholangiocarcinoma patients (HELIX-1), was presented at 2024 ASCO_GI on Jan 18.

Rani Therapeutics Reports Encouraging Initial Outcomes from Phase 1 Trial of Oral RT-111, an Anti-IL-12/23 Antibody.

Minoxidil, found in LONITEN Tablets manufactured by Pfizer, is a peripheral vasodilator that is commonly used to treat hypertension and alopecia.

Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.

CRC, marked by Wnt pathway hyperactivation and DKK1 regulation, is effectively countered by DKN-01, an IgG4 antibody that neutralizes DKK1.

The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Nitrofurantoin, an antibiotic medication approved in 1953 by Procter & Gamble, is used to treat uncomplicated lower urinary tract infections.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Phase 2 results of IL-27, PD-(L)1, VEGF blockade using casdozokitug, atezo, and bev in uHCC patients were presented at 2024 ASCO_GI on Jan 18th.